Treatment of Clozapine-Induced Hypersalivation Ipratropium Bromide

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Hypersalivation (Too much saliva) and drooling is a side effect experienced by 31% of people taking the antipsychotic clozapine. This study aims to determine if using the medication ipratropium bromide(IPB)at bedtime will reduce the amount of salivation and the distress people may feel.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre for Addiction and Mental Health
• Treatments: Bromides; Clozapine; Ipratropium

Criteria

Inclusion Criteria:

• Diagnosis of schizophrenia or schizoaffective disorder as per DSM IV-TR criteria

• Receiving clozapine for at least 2 months

• No change in their clozapine dose for at least 2 weeks

• Have a Clinical Global Impression scale score for hypersalivation of greater than or equal to 4

• Have the capacity to provide voluntary, informed consent

• Able to speak English

• Have a minimum score of 2 on the TNHS prior to study entry

• No change in medications for at least 2 weeks

Exclusion Criteria:

• Subjects with co-morbid medical conditions that could influence hypersalivation (e.g. Idiopathic Parkinson's Disease)

• Subjects currently receiving ipratropium bromide for the treatment of hypersalivation or other medical conditions

• History of narrow-angle glaucoma, prostatic hyperplasia or bladder neck obstruction

• History of an allergic reaction to ipratropium bromide